Search details
1.
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Am J Hematol
; 98(11): 1685-1698, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37548390
2.
Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
Ann Hematol
; 101(4): 837-846, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-35083527
3.
Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
Eur J Haematol
; 109(1): 50-57, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35299281
4.
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Eur J Haematol
; 107(2): 265-274, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-33998054
5.
Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.
Haematologica
; 105(2): 375-386, 2020.
Article
in English
| MEDLINE | ID: mdl-31097632
6.
Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.
Am J Hematol
; 95(10): 1148-1157, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-32602117
7.
Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Int J Mol Sci
; 21(17)2020 Aug 22.
Article
in English
| MEDLINE | ID: mdl-32842710
8.
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
Int J Mol Sci
; 21(8)2020 Apr 24.
Article
in English
| MEDLINE | ID: mdl-32344757
9.
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia.
Haematologica
; 104(3): 516-523, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30309854
10.
RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis.
Int J Mol Sci
; 20(22)2019 Nov 16.
Article
in English
| MEDLINE | ID: mdl-31744053
11.
Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
Am J Hematol
; 93(1): 23-30, 2018 01.
Article
in English
| MEDLINE | ID: mdl-28960408
12.
Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma.
Pediatr Blood Cancer
; 70(4): e30060, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36317675
13.
Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease.
Biol Blood Marrow Transplant
; 23(7): 1186-1192, 2017 Jul.
Article
in English
| MEDLINE | ID: mdl-28285080
14.
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Int J Mol Sci
; 18(2)2017 Feb 15.
Article
in English
| MEDLINE | ID: mdl-28212292
15.
miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
Ann Hematol
; 100(11): 2845-2847, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34291333
16.
Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.
Int J Mol Sci
; 17(12)2016 Dec 10.
Article
in English
| MEDLINE | ID: mdl-27973410
17.
Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.
Blood
; 131(7): 826-830, 2018 02 15.
Article
in English
| MEDLINE | ID: mdl-29295844
18.
TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model.
Ann Hematol
; 99(3): 653-655, 2020 Mar.
Article
in English
| MEDLINE | ID: mdl-32002654
19.
Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
Blood
; 130(7): 946-948, 2017 08 17.
Article
in English
| MEDLINE | ID: mdl-28679736
20.
Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.
Blood
; 129(18): 2587-2591, 2017 05 04.
Article
in English
| MEDLINE | ID: mdl-28258055